InnoCare Doses First Patient in Mesutoclax BCL2 Inhibitor Trial for MCL in China
InnoCare Pharma has dosed the first patient in a registrational trial of its BCL2 inhibitor, mesutoclax (ICP-248), for mantle...
InnoCare Pharma has dosed the first patient in a registrational trial of its BCL2 inhibitor, mesutoclax (ICP-248), for mantle...
The global knee replacement surgery market is projected to reach $16.17 billion by 2030, expanding at a 6.1% compound...
Septerna has dosed the first participants in a Phase 1 trial of SEP-631, an oral, selective, small molecule Mas-related...
Evoke Pharma has secured a new U.S. patent (No. 12,377,064) for the use of its GIMOTI (metoclopramide) nasal spray...
A Shenzhen-based medical team reports that 24 patients with Type 1 diabetes (T1DM) have discontinued insulin therapy following treatment...
A Shenzhen-based medical team reports that 24 patients with Type 1 diabetes (T1DM) have discontinued insulin therapy, achieving a...
NurExone Biologic Inc. has released new preclinical MRI-DTI (Diffusion Tensor Imaging) data for ExoPTEN, its exosome-based therapy for spinal...
Hutchmed has completed enrollment in its China Phase 3 SANOVO trial, evaluating the combination of savolitinib (Orpathys) and osimertinib...
HUTCHMED has completed enrollment in its China Phase III SANOVO trial evaluating savolitinib plus osimertinib as a first-line treatment...
COUR Pharma has dosed the first patient in a Phase 1b/2a trial of CNP-103, a tolerogenic nanoparticle therapy for...